X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs ABBOTT INDIA - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA ABBOTT INDIA GSK PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 66.0 34.6 190.8% View Chart
P/BV x 11.6 10.0 115.7% View Chart
Dividend Yield % 1.1 0.6 178.6%  

Financials

 GSK PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
ABBOTT INDIA
Mar-17
GSK PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs3,8385,190 73.9%   
Low Rs2,6374,351 60.6%   
Sales per share (Unadj.) Rs354.21,382.9 25.6%  
Earnings per share (Unadj.) Rs39.8130.2 30.5%  
Cash flow per share (Unadj.) Rs42.9137.9 31.1%  
Dividends per share (Unadj.) Rs30.0040.00 75.0%  
Dividend yield (eoy) %0.90.8 110.5%  
Book value per share (Unadj.) Rs236.9652.7 36.3%  
Shares outstanding (eoy) m84.7021.25 398.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.13.4 265.0%   
Avg P/E ratio x81.436.6 222.2%  
P/CF ratio (eoy) x75.534.6 218.3%  
Price / Book Value ratio x13.77.3 186.9%  
Dividend payout %75.430.7 245.6%   
Avg Mkt Cap Rs m274,216101,373 270.5%   
No. of employees `0004.73.1 152.4%   
Total wages/salary Rs m4,8303,453 139.9%   
Avg. sales/employee Rs Th6,387.09,531.9 67.0%   
Avg. wages/employee Rs Th1,028.31,119.9 91.8%   
Avg. net profit/employee Rs Th717.1897.3 79.9%   
INCOME DATA
Net Sales Rs m30,00029,387 102.1%  
Other income Rs m728576 126.3%   
Total revenues Rs m30,72829,963 102.6%   
Gross profit Rs m4,1903,973 105.5%  
Depreciation Rs m263164 160.1%   
Interest Rs m020 0.0%   
Profit before tax Rs m4,6554,365 106.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m4570-   
Tax Rs m1,7441,598 109.1%   
Profit after tax Rs m3,3682,767 121.7%  
Gross profit margin %14.013.5 103.3%  
Effective tax rate %37.536.6 102.3%   
Net profit margin %11.29.4 119.3%  
BALANCE SHEET DATA
Current assets Rs m16,74218,906 88.6%   
Current liabilities Rs m7,2026,297 114.4%   
Net working cap to sales %31.842.9 74.1%  
Current ratio x2.33.0 77.4%  
Inventory Days Days5262 83.3%  
Debtors Days Days2122 96.0%  
Net fixed assets Rs m8,6351,159 745.2%   
Share capital Rs m847213 398.6%   
"Free" reserves Rs m19,22213,657 140.7%   
Net worth Rs m20,06913,869 144.7%   
Long term debt Rs m100-   
Total assets Rs m30,03820,638 145.5%  
Interest coverage xNM215.0-  
Debt to equity ratio x00-  
Sales to assets ratio x1.01.4 70.1%   
Return on assets %11.213.5 83.0%  
Return on equity %16.819.9 84.1%  
Return on capital %25.531.6 80.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5280-   
Fx outflow Rs m7,1930-   
Net fx Rs m-6,6650-   
CASH FLOW
From Operations Rs m2,3603,072 76.8%  
From Investments Rs m3,008-1,554 -193.6%  
From Financial Activity Rs m-5,108-898 569.0%  
Net Cashflow Rs m260621 42.0%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 50.7 75.0 67.6%  
Indian inst/Mut Fund % 10.2 7.9 129.1%  
FIIs % 23.8 0.1 23,800.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 17.1 90.1%  
Shareholders   102,036 18,270 558.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   CADILA HEALTHCARE  FDC LTD.  SHASUN PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Cuts Losses; TCS Up 3%(Closing)

After opening the day in red, share markets in India witnessed volatile trading activity throughout the day but clawed back some gains in the final hours of the trading window.

Related Views on News

GSK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 6.4% YoY). Sales on the other hand came in at Rs 7 bn (down 4.5% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Jun 15, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS